Clinical prediction value of chemokine CCL21 level for acute coronary syndrome

Abstract

Objective To investigate the clinical prediction value of chemokine CCL21 level for acute coronary syndrome. Methods Totally 212 patients receiving coronary arteriography were divided into acute myocardial infarction group(AMI, n=72), unstable angina pectoris group(UAP, n=76), and stable angina pectoris group(SAP, n=64). The serum level of chemokine CCL21 was detected by double-antibody sandwich enzyme-linked immunosorbent assay(ELISA)and the pathological changes of coronary artery were measured by Gensini scoring system.All patients were followed up for six months and the cardiovascular adverse events were recorded. Results The serum level of CCL21 was(169.72±14.64)ng/L in AMI group, (154.42±16.50)ng/L in UAP group, and(143.87±9.80)ng/L in SAP group, with statistically significant differences(F=99.818, P=0.000). Serum levels of CCL21 in ACS group and SAP group were positively correlated with Gensini score(r=0.474, P=0.000; r=0.350, P=0.049). Binary Logistic regression analysis revealed that chemokine CCL21 was an independent risk factor for predicting acute coronary syndrome(OR=1.049, P=0.022). The CCL21-judged area under the ROC curve in acute coronary syndrome group was 0.887±0.028(P=0.000), with diagnostic point of serum level of chemokine CCL21 at 159.15 ng/L, sensitivity of 0.635, specificity of 0.981.Serum level of CCL21 was higher in the patients with cardiovascular adverse events than in the patients without cardiovascular adverse events〔(168.57±7.24)ng/L vs.(156.92±6.53)ng/L〕, with statistically significant difference(t=16.100, P=0.000). Conclusions Serum level of chemokine CCL21 reflects the severity degree of coronary artery disease.The chemokine CCL21, as an independent and effective marker, can predict acute coronary syndrome. Key words: Acute coronary syndrome; Chemokine CCL21